Hereditary Ovarian Cancer Panel
Use
This test is designed for individuals with relevant features who have a clinical or suspected diagnosis of hereditary ovarian cancer. It is also applicable for individuals with a current or past diagnosis of ovarian cancer, those of Ashkenazi Jewish ancestry with a personal or family history of breast/ovarian cancer, and individuals with a first or second degree relative diagnosed with ovarian cancer. The test can help in identifying genetic mutations that may increase the risk of ovarian cancer, thereby aiding in risk assessment and management.
Special Instructions
This test requires specific specimen types such as blood, buccal, saliva, or tissue. It is important for healthcare providers to obtain informed consent and ensure that the patient is counseled about the risks, benefits, and limitations of the genetic testing. STAT testing is available, but the surcharge applies unless the report is delivered after 16 days despite a blood sample submission. All testing must be ordered by a qualified healthcare provider.
Limitations
This test has not been cleared or approved by the US Food and Drug Administration. The accuracy of test results depends on the quality of clinical information provided. Genetic testing may not detect all mutations associated with ovarian cancer, and the implications of detected variants should be interpreted in the context of the entire clinical picture. Additionally, the presence of a variant does not necessarily confirm the presence of a disease, and genetic counseling is recommended to understand the implications of test results.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided